Margaret Fang, MD

Professor of Medicine

Margaret Fang is a clinician-investigator and the Research Director of the UCSF Division of Hospital Medicine. She also serves as the Medical Director of the UCSF Anticoagulation Clinic and the Director of the UCSF Academic Hospital Medicine Fellowship. After graduating from the Honors Program in Medical Education at Northwestern University Medical School, she completed her internal medicine residency training at the Beth Israel Deaconess Medical Center in Boston. She then obtained additional research training through a General Medicine Fellowship at the Massachusetts General Hospital and obtained a Masters of Public Health at the Harvard School of Public Health.
As a cardiovascular epidemiologist and clinical outcomes researcher, Margaret's research program focuses on how to optimize the use of anticoagulants to prevent stroke and treat venous thromboembolism. She is the Principal Investigator of the CVRN VTE and ALTERNATIVE Cohort Studies, cohorts of patients with venous thrombosis. She is also a core investigator in the ATRIA Study group, which investigates stroke and hemorrhage outcomes in patients with atrial fibrillation.
Education
2019 - Diversity, Equity, and Inclusion Champion Training, University of California
MPH, 2003 - , Harvard School of Public Health
General Medicine Fellowship, 2003 - , Massachusetts General Hospital
Internship/Residency, 2001 - Medicine, Beth Israel Deaconess Medical Center
MD, 1998 - , Northwestern University School of Medicine
BA, Molecular/Cell Biology, Honors Program in Medical Education, 1994 - , Northwestern University
Honors and Awards
  • Excellence in Research Award, Society of Hospital Medicine, 2010
  • Paul B. Beeson Career Development Award In Aging Research, NIH, AFAR, 2006
  • Hartford Geriatrics Health Outcomes Research Scholar, AGS Foundation for Health In Aging, 2005
  • Clinician Investigator of the Year, California Society of General Internal Medicine, 2005
  • Milton W. Hamolsky Award for best research abstract, Society of General Internal Medicine, 2005
  • Elizabeth Barrett-Connor Young Investigator Award, American Heart Association, 2004
  • Associate of the Year, Massachusetts American College of Physicians, 2002
  • Joseph E. Johnson National Leadership and Recognition Award, American College of Physicians, 2001
  • Lowell McGee Award for top resident teacher, Beth Israel Deaconess Medical Center, 2001
  • James Tullis Award for exceptional intellectual enthusiasm, Beth Israel Deaconess Medical Center, 2000
  • Jonathan Phillip Reder Award for excellence in academic and extracurricular activities, Northwestern University Medical School, 1997
  • A&O Award for Upcoming Student Leader, Northwestern University, 1994
Websites
Publications
  1. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
  2. Unexpected Heparin-Induced Thrombocytopenia While Bridging-Reply.
  3. Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study.
  4. Time to Recognition of Sepsis in the Emergency Department Using Electronic Health Record Data: A Comparative Analysis of Systemic Inflammatory Response Syndrome, Sequential Organ Failure Assessment, and Quick Sequential Organ Failure Assessment.
  5. Sex and Race/Ethnicity Differences in Atrial Fibrillation.
  6. Time to Recognition of Sepsis in the Emergency Department Using Electronic Health Record Data: A Comparative Analysis of Systemic Inflammatory Response Syndrome, Sequential Organ Failure Assessment, and Quick Sequential Organ Failure Assessment.
  7. Bridging Anticoagulation Therapy: A Teachable Moment.
  8. The Association between Limited English Proficiency and Sepsis Mortality.
  9. The Association between Limited English Proficiency and Sepsis Mortality.
  10. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation.
  11. Prevalence and Knowledge of Potential Interactions Between Over-the-Counter Products and Apixaban.
  12. Treatment and Outcomes of Acute Pulmonary Embolism and Deep Venous Thrombosis: The CVRN VTE Study.
  13. Aspirin Compared with Anticoagulation to Prevent Venous Thromboembolism After Knee or Hip Arthroplasty: a Large Retrospective Cohort Study.
  14. Predictive value of the present-on-admission indicator for hospital-associated hemorrhage.
  15. Trends and Racial Differences in First Hospitalization for Stroke and 30-Day Mortality in the US Medicare Population From 1988 to 2013.
  16. Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable.
  17. Reducing Unnecessary Treatment of Asymptomatic Elevated Blood Pressure with Intravenous Medications on the General Internal Medicine Wards: A Quality Improvement Initiative.
  18. Risk factors for medication non-adherence among atrial fibrillation patients.
  19. Periprocedural Bridging in Patients with Venous Thromboembolism: A Systematic Review.
  20. Electronic Order Volume as a Meaningful Component in Estimating Patient Complexity and Resident Physician Workload.
  21. Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study.
  22. An NGO-Implemented Community-Clinic Health Worker Approach to Providing Long-Term Care for Hypertension in a Remote Region of Southern India.
  23. Hospitalist and Internal Medicine Leaders' Perspectives of Early Discharge Challenges at Academic Medical Centers.
  24. Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism.
  25. Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study.
  26. Associations of Physician Empathy with Patient Anxiety and Ratings of Communication in Hospital Admission Encounters.
  27. Letter to the Editor, The Authors Reply, "What Can Be Done to Maintain Positive Patient Experience and Improve Residents' Satisfaction?" and vStandardized Attending Rounds to Improve the Patient Experience: A Pragmatic Cluster Randomized Controlled Trial"
  28. Dosing Accuracy of Direct Oral Anticoagulants in an Academic Medical Center.
  29. The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty.
  30. Health Literacy and Awareness of Atrial Fibrillation.
  31. Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding.
  32. Standardized Attending Rounds to Improve the Patient Experience: A Pragmatic Cluster Randomized Controlled Trial.
  33. Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke.
  34. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study.
  35. Low Diagnostic Utility of Rechecking Hemoglobins Within 24 Hours in Hospitalized Patients.
  36. Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
  37. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?
  38. Implementation and evaluation of a "works-in-progress" session to promote scholarship in an academic hospitalist group.
  39. How can I predict bleeding in my elderly patient taking anticoagulants?
  40. Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study.
  41. Anticoagulation in Older Adults with Multimorbidity.
  42. Initial management and outcomes after superficial thrombophlebitis: The Cardiovascular Research Network Venous Thromboembolism study.
  43. Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study.
  44. Assessment of algorithms to identify patients with thrombophilia following venous thromboembolism.
  45. Thrombophilia testing patterns amongst patients with acute venous thromboembolism.
  46. Outcomes in adults with acute pulmonary embolism who are discharged from emergency departments: the Cardiovascular Research Network Venous Thromboembolism study.
  47. Implications of the new atrial fibrillation guideline.
  48. Care as a continuum: will hospital outcomes be influenced by outpatient care?
  49. Assessment of Algorithms to Identify Patients with Thrombophilia Following Venous Thromboembolism.
  50. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study.
  51. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts).
  52. Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation.
  53. Contemporary use of dual antiplatelet therapy for preventing cardiovascular events.
  54. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin.
  55. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
  56. Trends in stroke rates, risk, and outcomes in the United States, 1988 to 2008.
  57. Long-term survival after ischemic stroke in patients with atrial fibrillation.
  58. Internal medicine rounding practices and the Accreditation Council for Graduate Medical Education core competencies.
  59. A pharmacogenetic versus a clinical algorithm for warfarin dosing.
  60. BOOST: evidence needing a lift.
  61. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score.
  62. Assessing bleeding risk in patients taking anticoagulants.
  63. DIGOXIN AND RISK OF DEATH IN ADULTS WITH ATRIAL FIBRILLATION: THE ATRIA-CVRN STUDY.
  64. Atrial fibrillation: stroke prevention in older adults.
  65. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants.
  66. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
  67. Selecting the optimal stroke prevention therapy in atrial fibrillation.
  68. Performance of an online translation tool when applied to patient educational material.
  69. Transitions in Care: Inpatient Anticoagulation.
  70. Hazards of hospitalization: more than just "never events".
  71. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.
  72. Use and outcomes of venous thromboembolism prophylaxis after spinal fusion surgery.
  73. Anticoagulation in people with atrial fibrillation.
  74. Warfarin discontinuation after starting warfarin for atrial fibrillation.
  75. CHA2DS2-VASc risk scheme: not ready for clinical use.
  76. Trends in thrombolytic use for ischemic stroke in the United States.
  77. Venous thromboembolism prophylaxis in the United States: still room for improvement.
  78. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism.
  79. Rates and predictors of plans for inferior vena cava filter retrieval in hospitalized patients.
  80. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation.
  81. The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
  82. Trends in catheter ablation for atrial fibrillation in the United States.
  83. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study.
  84. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.
  85. Language, literacy, and characterization of stroke among patients taking warfarin for stroke prevention: Implications for health communication.
  86. Antithrombotic therapy for the treatment of atrial fibrillation in the elderly.
  87. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
  88. The Reply:.
  89. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation.
  90. Atrial fibrillation in the elderly.
  91. Death and disability from warfarin-associated intracranial and extracranial hemorrhages.
  92. Preparing for "diastole": advanced training opportunities for academic hospitalists.
  93. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.
  94. Health literacy and anticoagulation-related outcomes among patients taking warfarin.
  95. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.
  96. Antithrombotic therapy for stroke prevention in atrial fibrillation.
  97. Cost considerations surrounding current and future anticoagulant therapies.
  98. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.
  99. Are patients more likely to see physicians of the same sex? Recent national trends in primary care medicine.
  100. Anticoagulation for atrial fibrillation.
  101. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation.
  102. Chapter 15 Anticoagulant and Antiplatelet Drug Therapy in Atrial Fibrillation.